<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45266">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01965626</url>
  </required_header>
  <id_info>
    <org_study_id>ITP-Oseltamivir</org_study_id>
    <secondary_id>ITP-Oseltamivirphosphate</secondary_id>
    <nct_id>NCT01965626</nct_id>
  </id_info>
  <brief_title>A Multicenter Randomized Open-label Study of Oseltamivir Combined With High-dose Dexamethasone Versus High-dose Dexamethasone in the Management of Immune Thrombocytopenia With High Platelet Desialylation Level</brief_title>
  <official_title>A Multicenter Randomized Open-label Study of Oseltamivir Combined With High-dose Dexamethasone Versus High-dose Dexamethasone in the Management of Immune Thrombocytopenia With High Platelet Desialylation Level</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Traditional Medicine Hospital of Zhejiang Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <authority>People's Republic of China: National Health and Family Planning Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oseltamivirphosphate is hydrolysed to its active metabolite-the free carboxylate of
      oseltamivir. Oseltamivir is a neuraminidase inhibitor, serving as a competitive inhibitor of
      the activity of the viral neuraminidase (NA) enzyme upon sialic acid, found on glycoproteins
      on the surface of platelets. By blocking the activity of the enzyme, oseltamivir may prevent
      platelet destruction in liver.The project was undertaking by Qilu Hospital of Shandong
      University and other 5 well-known hospitals in China. In order to report the efficacy and
      safety of oseltamivirphosphate combined with high-dose dexamethasone for the treatment of
      immune thrombocytopenia (ITP) with high platelet desialylation level, compared to high-dose
      dexamethasone therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are undertaking a parallel group, multicentre, randomised controlled trial
      of 240 newly diagnosed ITP adult patients with high platelet desialylation level from 6
      medical centers in China. One part of the participants are randomly selected to receive
      oseltamivirphosphate (oral administration at a dose of 75 mg twice for 5 consecutive days),
      combining with dexamethasone (given intravenously at a dose of 40 mg per day for 4 days, the
      others are selected to receive high-dose of dexamethasone treatment (given intravenously at
      a dose of 40 mg daily for 4 days).

      Platelet count, bleeding and other symptoms were evaluated before and after treatment.
      Adverse events are also recorded throughout the study. In order to report the efficacy and
      safety of oseltamivirphosphate combining with high-dose dexamethasone therapy compared to
      high-dose dexamethasone for the treatment of adults with newly diagnosed ITP with high
      platelet desialylation level.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluation of platelet response</measure>
    <time_frame>Newly diagnosed ITP in 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>R. A response (R) was defined as a sustained (≥ 3 months) platelet count ≥ 30×10^9/L without recurrence of thrombocytopenia</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Focus of Study</condition>
  <arm_group>
    <arm_group_label>Oseltamivir Combining HD-DXM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oseltamivir 75mg twice per day, 5 consecutive days Dexamethasone 40mg per day, 4 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HD-DXM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 40 mg per day, 4 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>Oseltamivir 75 mg twice per day, 5 consecutive days</description>
    <arm_group_label>Oseltamivir Combining HD-DXM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 40 mg per day, 4 consecutive days</description>
    <arm_group_label>Oseltamivir Combining HD-DXM</arm_group_label>
    <arm_group_label>HD-DXM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed ITP patients with high platelet desialylation level need of
             treatment(s) to minimize the risk of clinically significant bleeding primary ITP
             confirmed by excluding other supervened causes of thrombocytopenia

        Exclusion Criteria:

          -  pregnancy hypertension cardiovascular disease diabetes liver and kidney function
             impairment HCV, HIV, HBsAg seropositive status patients with systemic lupus
             erythematosus and/or antiphospholipid syndrome
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming Hou, Docter</last_name>
    <email>houming@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qilu hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Hou</last_name>
      <email>houming@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Ming Hou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan 14;115(2):168-86. Epub 2009 Oct 21. Review.</citation>
    <PMID>19846889</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 Mar 12;113(11):2386-93. Epub 2008 Nov 12.</citation>
    <PMID>19005182</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>October 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Ming Hou</investigator_full_name>
    <investigator_title>Professor and Director</investigator_title>
  </responsible_party>
  <keyword>Oseltamivir</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>ITP</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
